Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | glioma tissues |
| Expression Pattern | down-regulated |
| Function Description | Expression of lncRNAs MEG3, JPX, RNCR3, and ZFAS1 significantly differed between low and high malignancy grade. MEG3, JPX, RNCR3, and ZFAS1 showed significant decrease with tumour malignant progression. Expression of certain lncRNAs seems to be associated with patient's age at the time of diagnosis as correlation analysis showed moderate negative association for MEG3 (rs = 0.336, p = 0.009, R2 = 0.113), ZFAS1 (rs = 0.368, p = 0.004, R2 = 0.164), and RNCR3 (rs = 0.431, p = 0.001, R2 = 0.186). |
| Pubmed ID | 29138748 |
| Year | 2017 |
| Title | Identifying Novel Glioma-Associated Noncoding RNAs by Their Expression Profiles |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |